Evidence map›Paper›PMID 37058247›Full record

ArticleInternational journal of hematology2023

Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.

Yoko Edahiro, Tomonori Ochiai, Yoshinori Hashimoto, Soji Morishita, Shuichi Shirane, Tadaaki Inano, Chiho Furuya, Michiaki Koike, Masaaki Noguchi, Kensuke Usuki and 23 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 1 country.

Yoko EdahiroDepartment of Advanced Hematology, Juntendo University Graduate School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, Japan. yedahiro@juntendo.ac.jp.
Tomonori OchiaiDepartment of Advanced Hematology, Juntendo University Graduate School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, Japan.
Yoshinori HashimotoDepartment of Advanced Hematology, Juntendo University Graduate School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, Japan.
Soji MorishitaDepartment of Advanced Hematology, Juntendo University Graduate School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, Japan.
Shuichi ShiraneDepartment of Advanced Hematology, Juntendo University Graduate School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, Japan.
Tadaaki InanoDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Chiho FuruyaDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Michiaki KoikeDepartment of Hematology, Juntendo University Shizuoka Hospital, Izunokuni, Japan.
Masaaki NoguchiDepartment of Hematology, Juntendo University Urayasu Hospital, Urayasu, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Motoaki ShiratsuchiDepartment of Hematology, Iizuka Hospital, Iizuka, Japan.
Kei NakajimaDepartment of Hematology/Oncology, University of Yamanashi, Kofu, Japan.
Eiichi OhtsukaDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Hiroaki TanakaDepartment of Hematology, Asahi General Hospital, Asahi, Japan.
Eri KawataDepartment of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan.
Mika NakamaeDepartment of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yasunori UedaDepartment of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
Yasuo AotaDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Yasumasa SugitaDepartment of Hematology, Oami Municipal Hospital, Oamishirasato, Japan.
Shin OharaDepartment of Hematology, Eiju General Hospital, Tokyo, Japan.
Satoshi YamasakiDepartment of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan.
Kohsuke AsagoeDepartment of Hematology & Oncology, Shiga General Hospital, Moriyama, Japan.
Shuro YoshidaDepartment of Hematology, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.
Jun YamanouchiDivision of Blood Transfusion and Cell Therapy, Ehime University Hospital, Toon, Japan.
Sayaka SuzukiDepartment of Hematology, Tottori University Hospital, Yonago, Japan.
Toshinori KondoDepartment of Hematology, Kawasaki Medical School, Kurashiki, Japan.
Yuji KanisawaDepartment of Hematology and Oncology, Oji General Hospital, Tomakomai, Japan.
Kohtaro ToyamaDepartment of Hematology, Fujioka General Hospital, Fujioka, Japan.
Hiromi OmuraDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan.
Daisuke MizuchiDepartment of Hematology, Tokyo Teishin Hospital, Tokyo, Japan.
Sumio SakamakiDepartment of Hematology, Hokuou Hospital, Sapporo, Japan.
Miki AndoDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Norio KomatsuDepartment of Advanced Hematology, Juntendo University Graduate School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, Japan.
Juntendo University · JPAsahi Hospital · JPAso Iizuka Hospital · JPEhime University Hospital · JPEiju General Hospital · JPItami City Hospital · JPJuntendo University Shizuoka Hospital · JPJuntendo University Urayasu Hospital · JPKawasaki Medical School · JPKurashiki Central Hospital · JPKyushu University Beppu Hospital · JPMatsushita Memorial Hospital · JPNational Kyushu Medical Center · JPNTT Medical Center · JPOita Prefectural Hospital · JPOji General Hospital · JPShiga Medical Center · JPTokyo Metropolitan University · JPTokyo Teishin Hospital · JPTottori Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a rare disease, which presents with features of myelodysplastic syndromes with ring sideroblasts and essential thrombocythemia, as well as anemia and marked thrombocytosis. SF3B1 and JAK2 mutations are often found in patients, and are associated with their specific clinical features. This study was a retrospective analysis of 34 Japanese patients with MDS/MPN-RS-T. Median age at diagnosis was 77 (range, 51-88) years, and patients had anemia (median hemoglobin: 9.0 g/dL) and thrombocytosis (median platelet count: 642 × 109/L). Median overall survival was 70 (95% confidence interval: 68-not applicable) months during the median follow-up period of 26 (range: 0-91) months. A JAK2V617F mutation was detected in 46.2% (n = 12) of analyzed patients (n = 26), while an SF3B1 mutation was detected in 87.5% (n = 7) of analyzed patients (n = 8). Like those with myelodysplastic syndromes or myeloproliferative neoplasms, patients often received erythropoiesis-stimulating agents and aspirin to improve anemia and prevent thrombosis. This study, which was the largest to describe the real-world characteristics of Japanese patients with MDS/MPN-RS-T, showed that the patients had similar characteristics to those in western countries.

Indexed as

Anemia, SideroblasticMyelodysplastic-Myeloproliferative DiseasesMyelodysplastic SyndromesNeoplasmsThrombocytosisEast Asian PeopleHumansMutationRetrospective StudiesRNA Splicing FactorsRNA Splicing FactorsJAK2V617FJapanMDS/MPN-RS-TRing sideroblastsSF3B1

Identifiers

PMID37058247
OpenAlexW4365483762

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.